We are a non-profit screening clinic, providing endoscopy
and colonoscopy screening procedures.
We are dedicated to improving access for patients requiring screening services.
We are a non-profit 10-bed residential hospice,
providing 24-hour comfort and care to adults
with life-limiting illness, and their families.
We are a non-profit ambulatory vision care centre,
providing surgical procedures, clinical vision care,
education and research. We are affiliated
with University of Toronto’s Department of Ophthalmology and Vision Sciences.
We are a non-profit Eye Bank. We collect,
process and distribute donated human eyes
and tissue for sight-saving transplants.
We are a non-profit community care program,
providing on-sight and in-home services
for older adults and adults living with disabilities.
Our goal is to enhance social, intellectual and physical well-being.
We are a non-profit long-term care home with 350 residents.
We are a place where residents feel comfortable,
independent and part of our community.
Two years ago, Kelley noticed the vision in her right eye was starting to blur. “I would wake up in the morning and feel like my eye wasn’t focusing,” says Kelley. A Toronto native, Kelley needs to drive from the east end of the city to the downtown core for work. “I can’t drive anymore because my right eye is so bad. I wanted to make sure I prevent this from happening to my left eye.”
Kelley has Keratoconus. I disease that impacts one in every 4,000 Canadians. It occurs when the cornea — the clear, dome-shaped front surface of your eye — thins and gradually bulges outward into a cone shape.
If left untreated, Keratoconus leads to blurred vision, sensitivity to light and eventual blindness. If the disease progresses far enough, the only option to restore sight is a corneal transplant, where the cornea from a deceased donor eye is transplanted onto the eye of an individual with the disease.
The Kensington Vision and Research Centre is studying a new procedure to stop the progression of Keratoconus before a transplant is needed. Known as corneal collagen cross-linking surgery, or CXL, the procedure involves removing the surface layer of the cornea with a laser, and applying B12 vitamin combined with UV light to harden (cross-link) the cornea and stop the disease. With a globally tested success rate of 90-95 per cent, this procedure is the standard practice in other countries to halt the progression of the disease.
The study, which was supported by partner organizations across the province, involved performing the surgery on over 1,000 patients and tracking how well it worked in preventing progression of Keratoconus. The centre is now in the midst of processing the data for The Ministry of Health and Long-Term Care. Right now, the procedure is only available privately and can cost upwards of $2,500 per eye.
"It’s becoming the standard of care for people with this disease,” explains Dr. Wendy Hatch, the Research Manager at Kensington Eye Institute. She is also an Assistant Professor and the Co-Chair of the University of Toronto’s Department of Ophthalmology and Vision Science’s Quality Improvement Committee. “About 1,000 eyes received this cutting-edge therapy through the initiative, and many more Ontarians may benefit in the future.”
Because of the high-demand for the procedure, The Kensington Vision and Research Centre has been given additional funding from the Ministry for another 580 cases. The data from those cases will also be included in the study.
Kelley feels lucky to be part of phase two of the project. Because her right eye is past the point of treatment, she is eager to prevent her left eye from deteriorating. “I can’t imagine what it would be like to have both eyes blur completely,” says Kelley. Her hope for the future? “I hope to one day be able to drive again. I miss the freedom of being behind the wheel.”
Read about our Kensington Vision & Research Centre
Learn more about The Kensington Eye Institute